178 related articles for article (PubMed ID: 19610267)
1. Hypersensitivity pneumonitis following intravesical bacille Calmette-Guérin immunotherapy for superficial bladder cancer.
Um SJ; Lee SK; Yang DK
J Investig Allergol Clin Immunol; 2009; 19(3):230-2. PubMed ID: 19610267
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
3. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H
Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.
Gonzalez OY; Musher DM; Brar I; Furgeson S; Boktour MR; Septimus EJ; Hamill RJ; Graviss EA
Clin Infect Dis; 2003 Jan; 36(2):140-8. PubMed ID: 12522745
[TBL] [Abstract][Full Text] [Related]
5. Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy.
McParland C; Cotton DJ; Gowda KS; Hoeppner VH; Martin WT; Weckworth PF
Am Rev Respir Dis; 1992 Nov; 146(5 Pt 1):1330-3. PubMed ID: 1443892
[TBL] [Abstract][Full Text] [Related]
6. Intravesical bacille Calmette-Guérin-induced multiorgan failure after treatment for transitional cell carcinoma.
Kiely B; McLaughlin AM; Lynch TH; Keane J
Scand J Urol Nephrol; 2011 Sep; 45(4):278-80. PubMed ID: 21329482
[TBL] [Abstract][Full Text] [Related]
7. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
8. [Granulomatous pneumonia as a complication of intravesical BCG immunotherapy--a case report].
Rogoziński P; Taracha-Guz D; Pęcikiewicz P; Kachel T; Dubiel G; Wandzel P; Bruliński K
Pneumonol Alergol Pol; 2014; 82(2):163-9. PubMed ID: 24615200
[TBL] [Abstract][Full Text] [Related]
9. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
10. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
11. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.
Proctor DD; Chopra S; Rubenstein SC; Jokela JA; Uhl L
Am J Gastroenterol; 1993 Jul; 88(7):1112-5. PubMed ID: 8317415
[TBL] [Abstract][Full Text] [Related]
12. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity pneumonitis as a complication of intravesical BCG therapy for bladder cancer.
Carrasco Hernández L; Castaño Núñez ÁL; Rodríguez Portal JA
Arch Bronconeumol; 2016 Aug; 52(8):445-6. PubMed ID: 26920491
[No Abstract] [Full Text] [Related]
14. A thoracic tuberculous spondylodisctis after intravesical BCG immunotherapy of bladder cancer - Case report and literature review.
Dąbrowska M; Drabarek T; Muraszko-Klaudel A; Sławek J
Neurol Neurochir Pol; 2015; 49(6):460-6. PubMed ID: 26652884
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
16. Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report.
Seelig MH; Oldenburg WA; Klingler PJ; Blute ML; Pairolero PC
J Vasc Surg; 1999 Feb; 29(2):377-81. PubMed ID: 9950996
[TBL] [Abstract][Full Text] [Related]
17. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
Begnini KR; Buss JH; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
[TBL] [Abstract][Full Text] [Related]
19. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
20. [Granulomatous prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a case report].
Sai S; Sakakibara T; Takashi M; Sakata T; Miyake K
Hinyokika Kiyo; 1990 Aug; 36(8):953-5. PubMed ID: 2239600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
